Access Resources
6741 - 6750 of 7616 Results
Title
Year
- Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients2014RESTRICTEDTitle: Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patientsJournal Name: Journal of Clinical InvestigationPublisher: American Society for Clinical InvestigationVol: 124Issue #: 3Start Page: 1340End Page: 1349Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1172/jci71640Best OA location URL: http://www.jci.org/articles/view/71640/files/pdfCitation Count: 206
- Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials2014RESTRICTEDTitle: Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trialsJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 127Issue #: 6Start Page: 861End Page: 879Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00401-014-1256-4Best OA location URL: https://europepmc.org/articles/pmc4034750?pdf=renderCitation Count: 199
-
RESTRICTEDTitle: The effect of deep brain stimulation randomized by site on balance in Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 29Issue #: 7Start Page: 949End Page: 953Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.25831Best OA location URL: https://europepmc.org/articles/pmc4057940?pdf=renderCitation Count: 39
- Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease2014RESTRICTEDTitle: Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson diseaseJournal Name: Proceedings of the National Academy of SciencesPublisher: Proceedings of the National Academy of SciencesVol: 111Issue #: 7Start Page: 2626End Page: 2631Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1073/pnas.1318306111Best OA location URL: https://www.pnas.org/content/pnas/111/7/2626.full.pdfCitation Count: 334
-
RESTRICTEDTitle: Heterogeneity in primary dystonia: Lessons from THAP1, GNAL, and TOR1A in Amish‐MennonitesJournal Name: Movement DisordersPublisher: WileyVol: 29Issue #: 6Start Page: 812End Page: 818Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.25818Best OA location URL: https://europepmc.org/articles/pmc4013240?pdf=renderCitation Count: 36
-
RESTRICTEDTitle: Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from controlJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 2Start Page: 418End Page: 420Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.08.008Best OA location URL: https://escholarship.org/content/qt8m97s2kf/qt8m97s2kf.pdf?t=rsqp1sCitation Count: 29
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study2014RESTRICTEDTitle: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 13Issue #: 2Start Page: 141End Page: 149Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(13)70293-xBest OA location URL: https://europepmc.org/articles/pmc4643396?pdf=renderCitation Count: 553
- Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats2014RESTRICTEDTitle: Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian ratsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 77Issue #:Start Page: 1End Page: 8Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2013.09.017Best OA location URL: https://europepmc.org/articles/pmc3865178?pdf=renderCitation Count: 57
- Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury2014RESTRICTEDTitle: Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 10Issue #: 1SStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jalz.2013.12.011Best OA location URL: https://europepmc.org/articles/pmc4201593?pdf=renderCitation Count: 63
-
RESTRICTEDTitle: Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson DiseaseJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 71Issue #: 2Start Page: 141End Page: 141Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2013.5528Best OA location URL: https://europepmc.org/articles/pmc3940333?pdf=renderCitation Count: 202